{"id":"qa108-granules","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Flatulence"}]},"_chembl":{"chemblId":"CHEMBL564","moleculeType":"Small molecule","molecularWeight":"284.43"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"QA108 granules work by modulating the gut microbiome to produce beneficial effects on the host. The exact mechanism of action is not fully understood, but it is thought to involve the production of short-chain fatty acids and other metabolites that have anti-inflammatory and immunomodulatory effects.","oneSentence":"QA108 granules are a gut microbiome modulator.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:30:50.278Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of irritable bowel syndrome (IBS)"}]},"trialDetails":[{"nctId":"NCT07189169","phase":"PHASE3","title":"QA108 Phase III Study in Subjects With Intermediate AMD","status":"RECRUITING","sponsor":"Smilebiotek Zhuhai Limited","startDate":"2025-07-08","conditions":"Intermediate Age-Related Macular Degeneration","enrollment":400},{"nctId":"NCT05562219","phase":"PHASE2","title":"QA108 Phase II Study in Subjects With Intermediate Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Smilebiotek Zhuhai Limited","startDate":"2022-06-29","conditions":"Intermediate Age-Related Macular Degeneration","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":66524,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"QA108 granules","genericName":"QA108 granules","companyName":"Smilebiotek Zhuhai Limited","companyId":"smilebiotek-zhuhai-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"QA108 granules are a gut microbiome modulator. Used for Treatment of irritable bowel syndrome (IBS).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}